-

Global Animal Pharmaceuticals Markets 2021-2026 - Opportunities in Rising Expenditure for Animal Healthcare & Introduction of New Products - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Animal Pharmaceuticals Market (2021-2026) by Type, Product, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Animal Pharmaceuticals Market is estimated to be USD 19.3 Bn in 2021 and is expected to reach USD 28.16 Bn by 2026, growing at a CAGR of 7.85%.

Market Dynamics

The global animal pharmaceuticals market is being driven by rising milk and meat consumption, the rising trend of pet adoption, and the rising prevalence of foodborne and zoonotic illnesses. Animals are adopted for companionship or as a house or workplace security, which has made animals an essential aspect of human existence in our day.

Therefore it's necessary to look after their well-being and health. As a result, the deeper bond between humans and animals and the rising demand for pets are all driving the animal pharmaceuticals industry forward. In addition, as the economies are growing, governments and pharmaceutical firms are investing in animal healthcare, creating new opportunities for the market ahead.

However, the market's development is being restrained by rising costs and the government regulatory prohibitions on the animal pharmaceuticals industry.

Recent Developments

  • Elanco announces an agreement to acquire Kindred Biosciences for the expansion in pet health. - 16th June 2021.
  • Phibro Animal Health Corporation Acquires Business of Osprey Biotechnics, Inc.- 1st August 2019.

Company Profiles

Some of the companies covered in this report are Aratana Therapeutics, Inc., Bayer AG, BioPredic International, Boehringer Ingelheim International GmbH, etc.

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Shareholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

3.1 Introduction

3.2 Market Size and Segmentation

3.3 Market Outlook

4 Market Influencers

4.1 Drivers

4.1.1 Growing Adoption of Pets

4.1.2 Increasing Population of Livestock

4.1.3 Government Obligatory Medication and Vaccination

4.2 Restraints

4.2.1 Numerous Risk Associated with Animal Health APIs

4.3 Opportunities

4.3.1 Rising Expenditure for Animal Healthcare

4.3.2 Introduction of New Products

4.4 Challenges

4.4.1 Inadequate Knowledge and Availability in Low-Income Areas

4.5 Trends

5 Market Analysis

5.1 Regulatory Scenario

5.2 Porter's Five Forces Analysis

5.3 Impact of COVID-19

5.4 Ansoff Matrix Analysis

6 Global Animal Pharmaceuticals Market, By Type

6.1 Introduction

6.2 Vaccine

6.3 Veterinary Drugs

7 Global Animal Pharmaceuticals Market, By Product

7.1 Introduction

7.2 Anti-Inflammatories

7.3 Bronchodilators

7.4 Ectoparasiticides

7.5 Endoparasiticides

8 Global Animal Pharmaceuticals Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Laboratories

8.4 Veterinary Clinics

9 Global Animal Pharmaceuticals Market, By Geography

10 Competitive Landscape

10.1 Competitive Quadrant

10.2 Market Share Analysis

10.3 Strategic Initiatives

11 Company Profiles

  • Aratana Therapeutics, Inc
  • Bayer AG
  • BioPredic International
  • Bimeda Animal Health Ltd
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Veterinary Products USA
  • Elanco Animal Health Inc.
  • Eli Lilly & Company
  • Huvepharma, Inc.
  • Liberty Pharma INC
  • Merck & Co., Inc.
  • Perrigo Company plc
  • Phibro Animal Health Corp
  • Sanofi
  • Sparhawk Laboratories
  • Vetoquinol S.A.
  • Virbac SA
  • Zoetis Inc

For more information about this report visit https://www.researchandmarkets.com/r/abuhn6

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Bioremediation Technology & Services Global Strategic Business Report 2026 | Now Available with Latest Forecasts to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Bioremediation Technology & Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Bioremediation Technology & Services was valued at US$58.6 Billion in 2024 and is projected to reach US$87.5 Billion by 2030, growing at a CAGR of 6.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions...

North America B2C & B2B E-Commerce, Payments & AI Market Analysis Report 2026: Payments Landscape Shifts as Wallet Usage Rises but Cards Maintain Revenue Lead - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "North America B2C & B2B E-Commerce, Payments & AI" report has been added to ResearchAndMarkets.com's offering. This report analyzes how digital commerce, the evolving payments landscape, artificial intelligence, and B2B digital trade are reshaping retail, financial services, and enterprise operations across North America, providing in-depth coverage of market development, transaction infrastructure, consumer and business behavior, AI integration, and cross-...

Next Generation Drug Conjugates Market Trends and Global Forecasts, 2025-2035 - Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra Represent Milestones in Advanced Treatment Solutions - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Next Generation Drug Conjugates Market: Industry Trends and Global Forecasts, Till 2035" has been added to ResearchAndMarkets.com's offering. The global next-generation drug conjugates market is projected to surge from USD 4.2 billion in the current year to USD 15.5 billion by 2035, displaying a CAGR of 14.0% during the forecast period. Next-generation drug conjugates are emerging as significant targeted treatments, particularly for rare diseases and various cancer...
Back to Newsroom